Switzerland's Lonza Group said yesterday that it will use a novel
process developed by US-based biocatalysis company Codexis for the
synthesis of a key chiral pharmaceutical compound used in one of
the world's major human...
Pressure on pharma ingredient supplier Lonza has continued into the
first half of the year, with consistently low use of custom
manufacturing capacity and weak demand for biomanufacturing
contributing to a 37 per cent drop in operating...
Swiss fine chemicals company Siegfried has been insulated from the
general downturn in the chemicals industry, but has finally
succumbed and been forced to lose staff and cut back production,
writes Phil Taylor.
Dutch pharmaceuticals and chemicals group Akzo Nobel has reported a
small decline in sales in the first half of the year, although the
cost of ongoing restructuring caused net earnings to slump by
nearly a quarter to €245 million.